Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01084005
First received: March 9, 2010
Last updated: December 11, 2013
Last verified: December 2013
  Purpose

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: linagliptin
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase III Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin (5 mg) Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients (Age >= 70 Years) With Insufficient Glycaemic Control( HbA1c >= 7.0) Despite Metformin and/or Sulphonylurea and/or Insulin Therapy

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • HbA1c Change From Baseline to Week 24 [ Time Frame: Baseline and week 24 ] [ Designated as safety issue: No ]
    HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.


Secondary Outcome Measures:
  • HbA1c Change From Baseline to Week 6 [ Time Frame: Baseline and week 6 ] [ Designated as safety issue: No ]
    HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.

  • HbA1c Change From Baseline to Week 12 [ Time Frame: Baseline and week 12 ] [ Designated as safety issue: No ]
    HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.

  • HbA1c Change From Baseline to Week 18 [ Time Frame: Baseline and week 18 ] [ Designated as safety issue: No ]
    HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.

  • FPG Change From Baseline to Week 24 [ Time Frame: Baseline and week 24 ] [ Designated as safety issue: No ]
    This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin.

  • FPG Change From Baseline to Week 6 [ Time Frame: Baseline and week 6 ] [ Designated as safety issue: No ]
    This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.

  • FPG Change From Baseline to Week 12 [ Time Frame: Baseline and week 12 ] [ Designated as safety issue: No ]
    This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.

  • FPG Change From Baseline to Week 18 [ Time Frame: Baseline and week 18 ] [ Designated as safety issue: No ]
    This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.

  • Percentage of Patients With HbA1c <7.0% at Week 24 [ Time Frame: Baseline and week 24 ] [ Designated as safety issue: No ]
    The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%. Only patients with baseline HbA1c >= 7%

  • Percentage of Patients With HbA1c <7.0% at Week 24 [ Time Frame: Baseline and week 24 ] [ Designated as safety issue: No ]
    The percentage of patients with an HbA1c value below 7% at week 24 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.

  • Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% at Week 24 [ Time Frame: Baseline and week 24 ] [ Designated as safety issue: No ]
    The percentage of patients with an HbA1c reduction of ≥0.5% at week 24 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%

  • Number of Patients With Rescue Therapy [ Time Frame: week 24 ] [ Designated as safety issue: No ]
    The use of rescue therapy was planned for patients failing to achieve preset criteria based on glucose levels during the randomised treatment period of the trial


Enrollment: 241
Study Start Date: March 2010
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: linagliptin
patients receive linagliptin 5 mg tablets once daily
Drug: linagliptin
patients receive linagliptin 5 mg tablets once daily
Placebo Comparator: placebo
patients receive placebo tablets matching linagliptin 5 mg once daily
Drug: placebo
patients receive placebo matching linagliptin 5 mg once daily

  Eligibility

Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Type 2 diabetes mellitus
  2. HbA1c >= 7.0%
  3. Age >= 70 years
  4. Signed and dated written informed consent

Exclusion criteria:

  1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent
  2. Impaired hepatic function
  3. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins
  4. Treatment with anti-obesity drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01084005

  Hide Study Locations
Locations
Australia, New South Wales
1218.63.61005 Boehringer Ingelheim Investigational Site
Gosford, New South Wales, Australia
Australia, Queensland
1218.63.61006 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
Australia, South Australia
1218.63.61003 Boehringer Ingelheim Investigational Site
Adelaide, South Australia, Australia
1218.63.61002 Boehringer Ingelheim Investigational Site
Daw Park, South Australia, Australia
Australia, Victoria
1218.63.61007 Boehringer Ingelheim Investigational Site
East Ringwood, Victoria, Australia
1218.63.61001 Boehringer Ingelheim Investigational Site
Parkville, Victoria, Australia
1218.63.61004 Boehringer Ingelheim Investigational Site
Reservoir, Victoria, Australia
Canada, British Columbia
1218.63.10008 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Canada, Ontario
1218.63.10003 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1218.63.10005 Boehringer Ingelheim Investigational Site
Hawkesbury, Ontario, Canada
1218.63.10007 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1218.63.10006 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Canada, Quebec
1218.63.10001 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1218.63.10002 Boehringer Ingelheim Investigational Site
St-Romuald, Quebec, Canada
Canada, Saskatchewan
1218.63.10004 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
Denmark
1218.63.45007 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
1218.63.45003 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
1218.63.45002 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
1218.63.45001 Boehringer Ingelheim Investigational Site
Birkerød, Denmark
1218.63.45008 Boehringer Ingelheim Investigational Site
Hellerup, Denmark
1218.63.45006 Boehringer Ingelheim Investigational Site
Hillerød, Denmark
1218.63.45004 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
1218.63.45005 Bispebjerg Hospital
København NV, Denmark
Netherlands
1218.63.31008 Boehringer Ingelheim Investigational Site
Beek en Donk, Netherlands
1218.63.31007 Boehringer Ingelheim Investigational Site
Beerzerveld, Netherlands
1218.63.31012 Boehringer Ingelheim Investigational Site
Doetinchem, Netherlands
1218.63.31014 Boehringer Ingelheim Investigational Site
Etten-Leur, Netherlands
1218.63.31009 Boehringer Ingelheim Investigational Site
Oude Pekela, Netherlands
1218.63.31001 Boehringer Ingelheim Investigational Site
Tubbergen, Netherlands
Sweden
1218.63.46004 Boehringer Ingelheim Investigational Site
Göteborg, Sweden
1218.63.46003 Boehringer Ingelheim Investigational Site
Järfälla, Sweden
1218.63.46001 Boehringer Ingelheim Investigational Site
Malmö, Sweden
1218.63.46002 Boehringer Ingelheim Investigational Site
Sundsvall, Sweden
1218.63.46005 Boehringer Ingelheim Investigational Site
Uppsala, Sweden
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01084005     History of Changes
Other Study ID Numbers: 1218.63, 2009-015255-25
Study First Received: March 9, 2010
Results First Received: June 14, 2012
Last Updated: December 11, 2013
Health Authority: Australia: Dept of Health and Ageing Therapeutic Goods Admin
Canada: Health Canada
Denmark: Danish Medicines Agency
Netherlands: Central Committee Research Involving Human Subjects
Sweden: Medical Products Agency

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Linagliptin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 20, 2014